The US FDA has floated a variety of policies to combat the opioid epidemic in recent years, but addressing the crisis through opioid-sparing outcomes and the development of substitutable, non-opioid drugs may be the most difficult options to pursue following a series of votes from the agency's Anesthetic and Analgesic Drug Products Advisory Committee on Nov. 15.
Committee members encouraged FDA to adopt a high regulatory bar on both fronts. The panel voted 11-1, with one abstention,...





